Eric Aboagye - Publications

Imperial College London, London, England, United Kingdom 

183 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Li Y, Inglese M, Dubash S, Barnes C, Brickute D, Braga MC, Wang N, Beckley A, Heinzmann K, Allott L, Lu H, Chen C, Fu R, Carroll L, Aboagye EO. Consideration of Metabolite Efflux in Radiolabelled Choline Kinetics. Pharmaceutics. 13. PMID 34452207 DOI: 10.3390/pharmaceutics13081246  1
2021 Wang N, Brickute D, Braga M, Barnes C, Lu H, Allott L, Aboagye EO. Novel Non-Congeneric Derivatives of the Choline Kinase Alpha Inhibitor ICL-CCIC-0019. Pharmaceutics. 13. PMID 34371769 DOI: 10.3390/pharmaceutics13071078  1
2021 Allott L, Chen C, Braga M, Leung SFJ, Wang N, Barnes C, Brickute D, Carroll L, Aboagye EO. Detecting hypoxia using F-pretargeted IEDDA "click" chemistry in live cells. Rsc Advances. 11: 20335-20341. PMID 34178309 DOI: 10.1039/d1ra02482e  1
2021 Allott L, Amgheib A, Barnes C, Braga M, Brickute D, Wang N, Fu R, Ghaem-Maghami S, Aboagye EO. Radiolabelling an F biologic facile IEDDA "click" chemistry on the GE FASTLab™ platform. Reaction Chemistry & Engineering. 6: 1070-1078. PMID 34123410 DOI: 10.1039/d1re00117e  1
2021 Lu H, Cunnea P, Nixon K, Rinne N, Aboagye EO, Fotopoulou C. Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer. British Journal of Cancer. PMID 33473167 DOI: 10.1038/s41416-020-01252-2  0.01
2021 Hu Z, Cunnea P, Zhong Z, Lu H, Osagie OI, Campo L, Artibani M, Nixon K, Ploski J, Santana Gonzalez L, Alsaadi A, Wietek N, Damato S, Dhar S, Blagden SP, ... ... Aboagye EO, et al. The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33446563 DOI: 10.1158/1078-0432.CCR-20-2782  1
2021 Natoli M, Gallon J, Lu H, Amgheib A, Pinato DJ, Mauri FA, Marafioti T, Akarca AU, Ullmo I, Ip J, Aboagye EO, Brown R, Karadimitris A, Ghaem-Maghami S. Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression. Journal For Immunotherapy of Cancer. 9. PMID 33436485 DOI: 10.1136/jitc-2020-001519  1
2021 Ferris T, Carroll L, Jenner S, Aboagye EO. Use of radioiodine in nuclear medicine-A brief overview. Journal of Labelled Compounds & Radiopharmaceuticals. 64: 92-108. PMID 33091159 DOI: 10.1002/jlcr.3891  1
2020 Arshad MA, Gitau S, Tam H, Park WE, Patel NH, Rockall A, Aboagye EO, Bharwani N, Barwick TD. Optimal method for metabolic tumour volume assessment of cervical cancers with inter-observer agreement on [18F]-fluoro-deoxy-glucose positron emission tomography with computed tomography. European Journal of Nuclear Medicine and Molecular Imaging. PMID 33313962 DOI: 10.1007/s00259-020-05136-8  1
2020 Cesarec S, Robson JA, Carroll LS, Aboagye EO, Spivey AC. Direct incorporation of [ 18F] into aliphatic systems: A promising Mncatalysed labelling technique for PET imaging. Current Radiopharmaceuticals. PMID 32895047 DOI: 10.2174/1874471013666200907115026  1
2020 Dubash S, Inglese M, Mauri F, Kozlowski K, Trivedi P, Arshad M, Challapalli A, Barwick T, Al-Nahhas A, Stanbridge R, Lewanski C, Berry M, Bowen F, Aboagye EO. Spatial heterogeneity of radiolabeled choline positron emission tomography in tumors of patients with non-small cell lung cancer: first-in-patient evaluation of [F]fluoromethyl-(1,2-H)-choline. Theranostics. 10: 8677-8690. PMID 32754271 DOI: 10.7150/thno.47298  1
2020 Witney TH, Fortt R, Aboagye EO. Correction: Preclinical Assessment of Carboplatin Treatment Efficacy in Lung Cancer by 18F-ICMT-11-Positron Emission Tomography. Plos One. 15: e0235804. PMID 32645089 DOI: 10.1371/journal.pone.0235804  1
2020 Braga M, Kaliszczak M, Carroll L, Schug ZT, Heinzmann K, Baxan N, Benito A, Valbuena GN, Stribbling S, Beckley A, Mackay G, Mauri F, Latigo J, Barnes C, Keun H, ... ... Aboagye EO, et al. Tracing Nutrient Flux Following Monocarboxylate Transporter-1 Inhibition with AZD3965. Cancers. 12. PMID 32604836 DOI: 10.3390/cancers12061703  1
2020 Allott L, Brickute D, Chen C, Braga M, Barnes C, Wang N, Aboagye EO. Development of a fluorine-18 radiolabelled fluorescent chalcone: evaluated for detecting glycogen. Ejnmmi Radiopharmacy and Chemistry. 5: 17. PMID 32578021 DOI: 10.1186/s41181-020-00098-6  1
2020 Sharma R, Inglese M, Dubash S, Lu H, Pinato DJ, Sanghera C, Patel N, Chung A, Tait PD, Mauri F, Crum WR, Barwick TD, Aboagye EO. Monitoring response to transarterial chemoembolization in hepatocellular carcinoma using F-Fluorothymidine Positron Emission Tomography. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 32513905 DOI: 10.2967/jnumed.119.240598  1
2020 Tarkin JM, Wall C, Gopalan D, Aloj L, Manavaki R, Fryer TD, Aboagye EO, Bennett MR, Peters JE, Rudd JHF, Mason JC. Novel Approach to Imaging Active Takayasu Arteritis Using Somatostatin Receptor Positron Emission Tomography/Magnetic Resonance Imaging. Circulation. Cardiovascular Imaging. 13: e010389. PMID 32460529 DOI: 10.1161/CIRCIMAGING.119.010389  0.01
2020 Allott L, Aboagye EO. Chemistry Considerations for the Clinical Translation of Oncology PET Radiopharmaceuticals. Molecular Pharmaceutics. 17: 2245-2259. PMID 32433888 DOI: 10.1021/acs.molpharmaceut.0c00328  1
2020 Allott L, Dubash S, Aboagye EO. [F]FET-βAG-TOCA: The Design, Evaluation and Clinical Translation of a Fluorinated Octreotide. Cancers. 12. PMID 32252406 DOI: 10.3390/cancers12040865  1
2020 Avesani G, Arshad M, Lu H, Fotopoulou C, Cannone F, Melotti R, Aboagye E, Rockall A. Radiological assessment of Peritoneal Cancer Index on preoperative CT in ovarian cancer is related to surgical outcome and survival. La Radiologia Medica. PMID 32239470 DOI: 10.1007/s11547-020-01170-6  0.01
2020 Ordonez AA, Abhishek S, Singh AK, Klunk MH, Azad BB, Aboagye EO, Carroll L, Jain SK. Caspase-Based PET for Evaluating Pro-Apoptotic Treatments in a Tuberculosis Mouse Model. Molecular Imaging and Biology. PMID 32232626 DOI: 10.1007/S11307-020-01494-9  1
2020 Sarpaki S, Cortezon-Tamarit F, de Aguiar SRMM, Exner RM, Divall D, Arrowsmith RL, Ge H, Palomares FJ, Carroll L, Calatayud DG, Paisey SJ, Aboagye EO, Pascu SI. Radio- and nano-chemistry of aqueous Ga(iii) ions anchored onto graphene oxide-modified complexes. Nanoscale. PMID 32181455 DOI: 10.1039/C9Nr10145D  1
2020 Barnes EME, Xu Y, Benito A, Herendi L, Siskos AP, Aboagye EO, Nijhuis A, Keun HC. Lactic acidosis induces resistance to the pan-Akt inhibitor uprosertib in colon cancer cells. British Journal of Cancer. PMID 32152504 DOI: 10.1038/s41416-020-0777-y  1
2020 Dubash SR, Keat N, Kozlowski K, Barnes C, Allott L, Brickute D, Hill S, Huiban M, Barwick TD, Kenny L, Aboagye EO. Clinical translation of F-fluoropivalate - a PET tracer for imaging short-chain fatty acid metabolism: safety, biodistribution, and dosimetry in fed and fasted healthy volunteers. European Journal of Nuclear Medicine and Molecular Imaging. PMID 32123971 DOI: 10.1007/s00259-020-04724-y  1
2019 Glaser M, Rajkumar V, Diocou S, Gendron T, Yan R, Sin PKB, Sander K, Carroll L, Pedley RB, Aboagye EO, Witney TH, Årstad E. One-Pot Radiosynthesis and Biological Evaluation of a Caspase-3 Selective 5-[I]iodo-1,2,3-triazole derived Isatin SPECT Tracer. Scientific Reports. 9: 19299. PMID 31848442 DOI: 10.1038/s41598-019-55992-0  1
2019 Sharma R, Valls PO, Inglese M, Dubash S, Chen M, Gabra H, Montes A, Challapalli A, Arshad M, Tharakan G, Chambers E, Cole T, Lozano-Kuehne JP, Barwick TD, Aboagye EO. [F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer. European Journal of Nuclear Medicine and Molecular Imaging. PMID 31754793 DOI: 10.1007/s00259-019-04532-z  1
2019 Sharma R, Wang WM, Yusuf S, Evans J, Ramaswami R, Wernig F, Frilling A, Mauri F, Al-Nahhas A, Aboagye EO, Barwick TD. Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 31542317 DOI: 10.1016/j.radonc.2019.09.003  1
2019 Inglese M, Ordidge KL, Honeyfield L, Barwick TD, Aboagye EO, Waldman AD, Grech-Sollars M. Reliability of dynamic contrast-enhanced magnetic resonance imaging data in primary brain tumours: a comparison of Tofts and shutter speed models. Neuroradiology. 61: 1375-1386. PMID 31392385 DOI: 10.1007/s00234-019-02265-2  1
2019 Hernández-Gil J, Braga M, Harriss BI, Carroll LS, Leow CH, Tang MX, Aboagye EO, Long NJ. Development of Ga-labelled ultrasound microbubbles for whole-body PET imaging. Chemical Science. 10: 5603-5615. PMID 31293745 DOI: 10.1039/c9sc00684b  1
2019 Trousil S, Lee P, Edwards RJ, Maslen L, Lozan-Kuehne JP, Ramaswami R, Aboagye EO, Clarke S, Liddle C, Sharma R. Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation. British Journal of Pharmacology. PMID 31236938 DOI: 10.1111/bph.14776  1
2019 Ferris T, Carroll L, Mease RC, Spivey AC, Aboagye EO. Iodination of terminal alkynes using KI/CuSO - A facile method with potential for radio-iodination. Tetrahedron Letters. 60: 936-939. PMID 31217642 DOI: 10.1016/J.Tetlet.2019.02.041  1
2019 Leow CH, Bush NL, Stanziola A, Braga M, Shah A, Hernandez-Gil J, Long NJ, Aboagye EO, Bamber JC, Tang MX. 3D microvascular imaging using high frame rate ultrasound and ASAP without contrast agents: development and initial in vivo evaluation on non-tumour and tumour models. Ieee Transactions On Ultrasonics, Ferroelectrics, and Frequency Control. PMID 30908210 DOI: 10.1109/TUFFC.2019.2906434  1
2019 Brickute D, Braga M, Kaliszczak MA, Barnes C, Lau D, Carroll L, Stevens E, Trousil S, Alam IS, Nguyen QD, Aboagye EO. Development and Evaluation of an 18F-Radiolabeled Monocyclam Derivative for Imaging CXCR4 Expression. Molecular Pharmaceutics. PMID 30883140 DOI: 10.1021/acs.molpharmaceut.9b00069  1
2019 Przystal JM, Waramit S, Pranjol MZI, Yan W, Chu G, Chongchai A, Samarth G, Olaciregui NG, Tabatabai G, Carcaboso AM, Aboagye EO, Suwan K, Hajitou A. Efficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastoma. Embo Molecular Medicine. PMID 30808679 DOI: 10.15252/emmm.201708492  0.01
2019 Lavdas I, Glocker B, Rueckert D, Taylor SA, Aboagye EO, Rockall AG. Machine learning in whole-body MRI: experiences and challenges from an applied study using multicentre data. Clinical Radiology. PMID 30803815 DOI: 10.1016/j.crad.2019.01.012  1
2019 Vassileva V, Stribbling SM, Barnes C, Carroll L, Braga M, Abrahams J, Heinzmann K, Haegeman C, MacFarlane M, Simpson KL, Dive C, Honeychurch J, Illidge TM, Aboagye EO. Evaluation of apoptosis imaging biomarkers in a genetic model of cell death. Ejnmmi Research. 9: 18. PMID 30783791 DOI: 10.1186/s13550-019-0487-8  1
2019 Lu H, Arshad M, Thornton A, Avesani G, Cunnea P, Curry E, Kanavati F, Liang J, Nixon K, Williams ST, Hassan MA, Bowtell DDL, Gabra H, Fotopoulou C, Rockall A, ... Aboagye EO, et al. A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer. Nature Communications. 10: 764. PMID 30770825 DOI: 10.1038/s41467-019-08718-9  0.01
2019 Pinato DJ, Brown MW, Trousil S, Aboagye EO, Beaumont J, Zhang H, Coley HM, Mauri FA, Sharma R. Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma. British Journal of Cancer. PMID 30765873 DOI: 10.1038/s41416-018-0373-6  1
2019 Theodorou IG, Ruenraroengsak P, Gonzalez-Carter DA, Jiang Q, Yagüe E, Aboagye EO, Coombes RC, Porter AE, Ryan MP, Xie F. Towards multiplexed near-infrared cellular imaging using gold nanostar arrays with tunable fluorescence enhancement. Nanoscale. PMID 30648720 DOI: 10.1039/c8nr09409h  1
2018 Kaliszczak M, van Hechanova E, Li Y, Alsadah H, Parzych K, Auner HW, Aboagye EO. The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death. British Journal of Cancer. PMID 30318510 DOI: 10.1038/s41416-018-0232-5  1
2018 Dubash SR, Merchant S, Heinzmann K, Mauri F, Lavdas I, Inglese M, Kozlowski K, Rama N, Masrour N, Steel JF, Thornton A, Lim AK, Lewanski C, Cleator S, Coombes RC, ... ... Aboagye EO, et al. Clinical translation of [F]ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. PMID 30259091 DOI: 10.1007/s00259-018-4098-9  1
2018 Fu R, Carroll L, Yahioglu G, Aboagye E, Miller P. Antibody Fragment and Affibody ImmunoPET Imaging Agents: Radiolabelling Strategies and Applications. Chemmedchem. PMID 30246488 DOI: 10.1002/cmdc.201800624  1
2018 Arshad MA, Thornton A, Lu H, Tam H, Wallitt K, Rodgers N, Scarsbrook A, McDermott G, Cook GJ, Landau D, Chua S, O'Connor R, Dickson J, Power DA, Barwick TD, ... ... Aboagye EO, et al. Discovery of pre-therapy 2-deoxy-2-F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. PMID 30173391 DOI: 10.1007/s00259-018-4139-4  1
2018 Theodorou IG, Jiang Q, Malms L, Xie X, Coombes RC, Aboagye EO, Porter AE, Ryan MP, Xie F. Fluorescence enhancement from single gold nanostars: towards ultra-bright emission in the first and second near-infrared biological windows. Nanoscale. PMID 30105338 DOI: 10.1039/c8nr04567d  1
2018 Lledos M, Mirabello V, Sarpaki S, Ge H, Smugowski HJ, Carroll L, Aboagye EO, Aigbirhio FI, Botchway SW, Dilworth JR, Calatayud DG, Plucinski PK, Price GJ, Pascu SI. Synthesis, Radiolabelling and In Vitro Imaging of Multifunctional Nanoceramics. Chemnanomat : Chemistry of Nanomaterials For Energy, Biology and More. 4: 361-372. PMID 29938196 DOI: 10.1002/cnma.201700378  1
2018 Rupniewska E, Roy R, Mauri FA, Liu X, Kaliszczak M, Bellezza G, Cagini L, Barbareschi M, Ferrero S, Tommasi AM, Aboagye E, Seckl MJ, Pardo OE. Targeting autophagy sensitises lung cancer cells to Src family kinase inhibitors. Oncotarget. 9: 27346-27362. PMID 29937990 DOI: 10.18632/oncotarget.25213  1
2018 Heinzmann K, Nguyen QD, Honess DJ, Smith DM, Stribbling S, Brickute D, Barnes C, Griffiths JR, Aboagye EO. Depicting changes in tumor biology in response to cetuximab mono- or combination therapy by apoptosis and proliferation imaging using F-ICMT-11 and 3'-Deoxy-3'-[F]Fluorothymidine (F-FLT) PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29794225 DOI: 10.2967/jnumed.118.209304  1
2018 Lavdas I, Rockall AG, Daulton E, Kozlowski K, Honeyfield L, Aboagye EO, Sharma R. Histogram analysis of apparent diffusion coefficient from whole-body diffusion-weighted MRI to predict early response to chemotherapy in patients with metastatic colorectal cancer: preliminary results. Clinical Radiology. PMID 29793720 DOI: 10.1016/j.crad.2018.04.011  1
2018 Campbell S, Suwan K, Waramit S, Aboagye EO, Hajitou A. Selective Inhibition of Histone Deacetylation in Melanoma Increases Targeted Gene Delivery by a Bacteriophage Viral Vector. Cancers. 10. PMID 29690504 DOI: 10.3390/cancers10040125  0.01
2018 Patel H, Periyasamy M, Sava GP, Bondke A, Slafer BW, Kroll SHB, Barbazanges M, Starkey R, Ottaviani S, Harrod A, Aboagye EO, Buluwela L, Fuchter MJ, Barrett AGM, Coombes C, et al. ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. Molecular Cancer Therapeutics. PMID 29545334 DOI: 10.1158/1535-7163.Mct-16-0847  0.01
2018 Schelhaas S, Wachsmuth L, Hermann S, Rieder N, Heller A, Heinzmann K, Honess DJ, Smith DM, Fricke IB, Just N, Doblas S, Sinkus R, Döring C, Schäfers KP, Griffiths JR, ... ... Aboagye EO, et al. Thymidine Metabolism as Confounding Factor of 3'-Deoxy-3'-[F]Fluorothymidine Uptake after Therapy in a Colorectal Cancer Model. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29476002 DOI: 10.2967/jnumed.117.206250  1
2018 Kramer GM, Liu Y, de Langen AJ, Jansma EP, Trigonis I, Asselin MC, Jackson A, Kenny L, Aboagye EO, Hoekstra OS, Boellaard R. Repeatability of quantitative 18F-FLT uptake measurements in solid tumors: an individual patient data multi-center meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging. PMID 29362858 DOI: 10.1007/S00259-017-3923-X  1
2018 Cowell S, Carroll L, Lavdas I, Aboagye EO, Vilar R. Towards an MMP-2-activated molecular agent for cancer imaging. Dalton Transactions (Cambridge, England : 2003). PMID 29318240 DOI: 10.1039/C7Dt03108D  1
2017 Heinzmann K, Carter LM, Lewis JS, Aboagye EO. Multiplexed imaging for diagnosis and therapy. Nature Biomedical Engineering. 1: 697-713. PMID 31015673 DOI: 10.1038/S41551-017-0131-8  1
2017 Heinzmann K, Honess DJ, Lewis DY, Smith DM, Cawthorne C, Keen H, Heskamp S, Schelhaas S, Witney TH, Soloviev D, Williams KJ, Jacobs AH, Aboagye EO, Griffiths JR, Brindle KM. Correction to: The relationship between endogenous thymidine concentrations and [18F]FLT uptake in a range of preclinical tumour models. Ejnmmi Research. 7: 99. PMID 29247446 DOI: 10.1186/S13550-017-0349-1  1
2017 Schelhaas S, Heinzmann K, Honess DJ, Smith DM, Keen H, Heskamp S, Witney TH, Besret L, Doblas S, Griffiths JR, Aboagye EO, Jacobs AH. 3'-Deoxy-3'-[(18)F]Fluorothymidine Uptake Is Related to Thymidine Phosphorylase Expression in Various Experimental Tumor Models. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 28971330 DOI: 10.1007/s11307-017-1125-3  1
2017 Saleem A, Searle GE, Kenny LM, Huiban M, Kozlowski K, Waldman AD, Woodley L, Palmieri C, Lowdell C, Kaneko T, Murphy PS, Lau MR, Aboagye EO, Coombes RC. Erratum to: Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer. Ejnmmi Research. 7: 76. PMID 28921454 DOI: 10.1186/s13550-017-0325-9  1
2017 Saleem A, Searle GE, Kenny LM, Huiban M, Kozlowski K, Waldman AD, Woodley L, Palmieri C, Lowdell C, Kaneko T, Murphy PS, Lau MR, Aboagye EO, Coombes RC. Erratum to: Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer. Ejnmmi Research. 7: 74. PMID 28887806 DOI: 10.1186/s13550-017-0323-y  1
2017 Lavdas I, Glocker B, Kamnitsas K, Rueckert D, Mair H, Sandhu A, Taylor SA, Aboagye EO, Rockall AG. Fully automatic, multi-organ segmentation in normal whole body magnetic resonance imaging (MRI), using classification forests (CFs), convolutional neural networks (CNNs) and a multi-atlas (MA) approach. Medical Physics. PMID 28756622 DOI: 10.1002/mp.12492  1
2017 Aboagye EO, Kraeber-Bodéré F. Highlights lecture EANM 2016: "Embracing molecular imaging and multi-modal imaging: a smart move for nuclear medicine towards personalized medicine". European Journal of Nuclear Medicine and Molecular Imaging. 44: 1559-1574. PMID 28597119 DOI: 10.1007/s00259-017-3704-6  0.01
2017 Challapalli A, Carroll L, Aboagye EO. Molecular mechanisms of hypoxia in cancer. Clinical and Translational Imaging. 5: 225-253. PMID 28596947 DOI: 10.1007/s40336-017-0231-1  1
2017 Cysouw MCF, Kramer GM, Frings V, De Langen AJ, Wondergem MJ, Kenny LM, Aboagye EO, Kobe C, Wolf J, Hoekstra OS, Boellaard R. Baseline and longitudinal variability of normal tissue uptake values of [(18)F]-fluorothymidine-PET images. Nuclear Medicine and Biology. 51: 18-24. PMID 28528264 DOI: 10.1016/j.nucmedbio.2017.05.002  1
2017 Valindria VV, Lavdas I, Bai W, Kamnitsas K, Aboagye EO, Rockall AG, Rueckert D, Glocker B. Reverse Classification Accuracy: Predicting Segmentation Performance in the Absence of Ground Truth. Ieee Transactions On Medical Imaging. PMID 28436849 DOI: 10.1109/TMI.2017.2665165  1
2017 Schelhaas S, Heinzmann K, Bollineni VR, Kramer GM, Liu Y, Waterton JC, Aboagye EO, Shields AF, Soloviev D, Jacobs AH. Preclinical Applications of 3'-Deoxy-3'-[(18)F]Fluorothymidine in Oncology - A Systematic Review. Theranostics. 7: 40-50. PMID 28042315 DOI: 10.7150/Thno.16676  1
2016 Hoogenboom TC, Thursz M, Aboagye EO, Sharma R. Functional imaging of hepatocellular carcinoma. Hepatic Oncology. 3: 137-153. PMID 30191034 DOI: 10.2217/hep-2015-0005  1
2016 Sharma R, Mapelli P, Hanna GB, Goldin R, Power D, Al-Nahhas A, Merchant S, Ramaswami R, Challapalli A, Barwick T, Aboagye EO. Evaluation of (18)F-fluorothymidine positron emission tomography ([(18)F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer. Ejnmmi Research. 6: 81. PMID 27854031 DOI: 10.1186/s13550-016-0234-3  1
2016 O'Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, Boellaard R, Bohndiek SE, Brady M, Brown G, Buckley DL, Chenevert TL, Clarke LP, Collette S, Cook GJ, et al. Imaging biomarker roadmap for cancer studies. Nature Reviews. Clinical Oncology. PMID 27725679 DOI: 10.1038/Nrclinonc.2016.162  1
2016 Slade RL, Pisaneschi F, Nguyen QD, Smith G, Carroll L, Beckley A, Kaliszczak MA, Aboagye EO. Identification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission Tomography. Plos One. 11: e0161427. PMID 27552105 DOI: 10.1371/journal.pone.0161427  1
2016 Heinzmann K, Honess DJ, Lewis DY, Smith DM, Cawthorne C, Keen H, Heskamp S, Schelhaas S, Witney TH, Soloviev D, Williams KJ, Jacobs AH, Aboagye EO, Griffiths JR, Brindle KM. The relationship between endogenous thymidine concentrations and [(18)F]FLT uptake in a range of preclinical tumour models. Ejnmmi Research. 6: 63. PMID 27515446 DOI: 10.1186/S13550-016-0218-3  1
2016 Kaliszczak M, Trousil S, Ali T, Aboagye EO. AKT activation controls cell survival in response to HDAC6 inhibition. Cell Death & Disease. 7: e2286. PMID 27362804 DOI: 10.1038/cddis.2016.180  1
2016 Theodorou IG, Jawad ZA, Qin H, Aboagye EO, Porter AE, Ryan MP, Xie F. Significant metal enhanced fluorescence of Ag2S quantum dots in the second near-infrared window. Nanoscale. PMID 27314986 DOI: 10.1039/c6nr03220f  1
2016 Trousil S, Kaliszczak M, Schug Z, Nguyen Q, Tomasi G, Favicchio R, Brickute D, Fortt R, Twyman FJ, Carroll L, Kalusa A, Navaratnam N, Adejumo T, Carling D, Gottlieb E, ... Aboagye EO, et al. The novel choline kinase inhibitor ICL-CCIC-0019 reprograms cellular metabolism and inhibits cancer cell growth. Oncotarget. PMID 27206796 DOI: 10.18632/Oncotarget.9466  1
2016 Dubash SR, Keat N, Mapelli P, Twyman F, Carroll L, Kozlowski K, Al-Nahhas A, Saleem A, Huiban M, Janisch R, Frilling A, Sharma R, Aboagye E. Clinical Translation of a 'Click' Labeled 18F-Octreotate Radioligand for Imaging Neuroendocrine Tumors. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27173162 DOI: 10.2967/jnumed.115.169532  1
2016 Peck B, Schug ZT, Zhang Q, Dankworth B, Jones DT, Smethurst E, Patel R, Mason S, Jiang M, Saunders R, Howell M, Mitter R, Spencer-Dene B, Stamp G, McGarry L, ... ... Aboagye EO, et al. Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments. Cancer & Metabolism. 4: 6. PMID 27042297 DOI: 10.1186/S40170-016-0146-8  1
2016 Challapalli A, Aboagye EO. Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response Monitoring. Frontiers in Oncology. 6: 44. PMID 26973812 DOI: 10.3389/fonc.2016.00044  1
2016 Alam IS, Arrowsmith RL, Cortezon-Tamarit F, Twyman F, Kociok-Köhn G, Botchway SW, Dilworth JR, Carroll L, Aboagye EO, Pascu SI. Correction: Microwave gallium-68 radiochemistry for kinetically stable bis(thiosemicarbazone) complexes: structural investigations and cellular uptake under hypoxia. Dalton Transactions (Cambridge, England : 2003). PMID 26853056 DOI: 10.1039/C6Dt90021F  1
2016 Mazarico JM, Sánchez-Arévalo Lobo VJ, Favicchio R, Greenhalf W, Costello E, Carrillo-de Santa Pau E, Marqués M, Lacal JC, Aboagye E, Real FX. Choline Kinase Alpha (CHKα) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors. Molecular Cancer Therapeutics. 15: 323-33. PMID 26769123 DOI: 10.1158/1535-7163.Mct-15-0214  0.01
2015 George GPC, Pisaneschi F, Nguyen QD, Aboagye EO. Positron Emission Tomographic Imaging of CXCR4 in Cancer: Challenges and Promises. Molecular Imaging. 14: 7290201400041. PMID 28654396 DOI: 10.2310/7290.2014.00041  1
2015 Hopkins TG, Mura M, Al-Ashtal HA, Lahr RM, Abd-Latip N, Sweeney K, Lu H, Weir J, El-Bahrawy M, Steel JH, Ghaem-Maghami S, Aboagye EO, Berman AJ, Blagden SP. The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer. Nucleic Acids Research. PMID 26717985 DOI: 10.1093/Nar/Gkv1515  1
2015 Alam IS, Arrowsmith RL, Cortezon-Tamarit F, Twyman F, Kociok-Köhn G, Botchway SW, Dilworth JR, Carroll L, Aboagye EO, Pascu SI. Microwave gallium-68 radiochemistry for kinetically stable bis(thiosemicarbazone) complexes: structural investigations and cellular uptake under hypoxia. Dalton Transactions (Cambridge, England : 2003). PMID 26583314 DOI: 10.1039/C5Dt02537K  1
2015 Allott L, Smith G, Aboagye EO, Carroll L. PET Imaging of Steroid Hormone Receptor Expression. Molecular Imaging. 14: 11-22. PMID 26505328 DOI: 10.2310/7290.2015.00026  1
2015 Sharma R, Kallur K, Ryu J, Parameswaran R, Lindman H, Avril N, Gleeson F, Lee J, Lee KH, O'Doherty M, Groves A, Miller M, Somer E, Coombes C, Aboagye E. Multi-Centre Reproducibility of 18F-Fluciclatide PET Imaging in Subjects with Solid Tumors. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 26383153 DOI: 10.2967/jnumed.115.158253  1
2015 Lavdas I, Rockall AG, Castelli F, Sandhu RS, Papadaki A, Honeyfield L, Waldman AD, Aboagye EO. Apparent Diffusion Coefficient of Normal Abdominal Organs and Bone Marrow From Whole-Body DWI at 1.5 T: The Effect of Sex and Age. Ajr. American Journal of Roentgenology. 205: 242-50. PMID 26204271 DOI: 10.2214/AJR.14.13964  1
2015 Challapalli A, Trousil S, Hazell S, Kozlowski K, Gudi M, Aboagye EO, Mangar S. Exploiting altered patterns of choline kinase-alpha expression on human prostate tissue to prognosticate prostate cancer. Journal of Clinical Pathology. 68: 703-9. PMID 26041862 DOI: 10.1136/jclinpath-2015-202859  1
2015 Saleem A, Searle GE, Kenny LM, Huiban M, Kozlowski K, Waldman AD, Woodley L, Palmieri C, Lowdell C, Kaneko T, Murphy PS, Lau MR, Aboagye EO, Coombes RC. Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer. Ejnmmi Research. 5: 30. PMID 25977884 DOI: 10.1186/s13550-015-0103-5  1
2015 Hoyng LL, Frings V, Hoekstra OS, Kenny LM, Aboagye EO, Boellaard R. Metabolically active tumour volume segmentation from dynamic [(18)F]FLT PET studies in non-small cell lung cancer. Ejnmmi Research. 5: 26. PMID 25932353 DOI: 10.1186/s13550-015-0102-6  1
2015 Udemba A, Smith G, Nguyen QD, Kaliszczak M, Carroll L, Fortt R, Fuchter MJ, Aboagye EO. Design, synthesis and initial characterisation of a radiolabelled [(18)F]pyrimidoindolone probe for detecting activated caspase-3/7. Organic & Biomolecular Chemistry. 13: 5418-23. PMID 25865735 DOI: 10.1039/C5Ob00058K  1
2015 Carroll L, Evans HL, Spivey AC, Aboagye EO. Mn-salen catalysed benzylic C-H activation for the synthesis of aryl [(18)F]CF3-containing PET probes. Chemical Communications (Cambridge, England). 51: 8439-41. PMID 25714781 DOI: 10.1039/C4Cc05762G  1
2015 Challapalli A, Barwick T, Pearson RA, Merchant S, Mauri F, Howell EC, Sumpter K, Maxwell RJ, Aboagye EO, Sharma R. 3'-Deoxy-3'-¹⁸F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer. European Journal of Nuclear Medicine and Molecular Imaging. 42: 831-40. PMID 25673055 DOI: 10.1007/s00259-015-3000-2  1
2015 Alam IS, Arshad MA, Nguyen QD, Aboagye EO. Radiopharmaceuticals as probes to characterize tumour tissue. European Journal of Nuclear Medicine and Molecular Imaging. 42: 537-61. PMID 25647074 DOI: 10.1007/s00259-014-2984-3  1
2015 Schug ZT, Peck B, Jones DT, Zhang Q, Grosskurth S, Alam IS, Goodwin LM, Smethurst E, Mason S, Blyth K, McGarry L, James D, Shanks E, Kalna G, Saunders RE, ... ... Aboagye EO, et al. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell. 27: 57-71. PMID 25584894 DOI: 10.1016/J.Ccell.2014.12.002  1
2015 AbuAli G, Chaisaklert W, Stelloo E, Pazarentzos E, Hwang MS, Qize D, Harding SV, Al-Rubaish A, Alzahrani AJ, Al-Ali A, Sanders TA, Aboagye EO, Grimm S. The anticancer gene ORCTL3 targets stearoyl-CoA desaturase-1 for tumour-specific apoptosis. Oncogene. 34: 1718-28. PMID 24769897 DOI: 10.1038/onc.2014.93  1
2015 Saleem A, Searle GE, Kenny LM, Huiban M, Kozlowski K, Waldman AD, Woodley L, Palmieri C, Lowdell C, Kaneko T, Murphy PS, Lau MR, Aboagye EO, Coombes RC. Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer Ejnmmi Research. 5. DOI: 10.1186/s13550-015-0103-5  1
2015 Trousil S, Kalisczcak M, Schug Z, Nguyen Q, Tomasi G, Favicchio R, Brickute D, Fortt R, Twyman FJ, Carroll L, Kalusa A, Navaratnam N, Adejumo T, Carling D, Gottlieb E, ... Aboagye EO, et al. Abstract C118: Choline kinase inhibition with the novel pharmacological inhibitor ICL-CCIC-0019 reprograms cellular metabolism and inhibits cancer cell growth Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C118  1
2014 Gallo J, Alam IS, Lavdas I, Wylezinska-Arridge M, Aboagye EO, Long NJ. RGD-targeted MnO nanoparticles as T contrast agents for cancer imaging - the effect of PEG length in vivo. Journal of Materials Chemistry. B. 2: 868-876. PMID 32261318 DOI: 10.1039/c3tb21422b  1
2014 Kenny LM, Tomasi G, Turkheimer F, Larkin J, Gore M, Brock CS, Mangar S, Aboagye EO. Preliminary clinical assessment of the relationship between tumor alphavbeta3 integrin and perfusion in patients studied with [(18)F]fluciclatide kinetics and [ (15)O]H 2O PET. Ejnmmi Research. 4: 30. PMID 26055935 DOI: 10.1186/s13550-014-0030-x  1
2014 Lake MC, Aboagye EO. Luciferase fragment complementation imaging in preclinical cancer studies. Oncoscience. 1: 310-25. PMID 25594026 DOI: 10.18632/oncoscience.45  0.01
2014 Mura M, Hopkins TG, Michael T, Abd-Latip N, Weir J, Aboagye E, Mauri F, Jameson C, Sturge J, Gabra H, Bushell M, Willis AE, Curry E, Blagden SP. LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression. Oncogene. PMID 25531318 DOI: 10.1038/onc.2014.428  1
2014 Mapelli P, Aboagye EO, Stebbing J, Sharma R. Epigenetic changes in gastroenteropancreatic neuroendocrine tumours. Oncogene. PMID 25435371 DOI: 10.1038/onc.2014.379  1
2014 Willaime JM, Aboagye EO, Tsoumpas C, Turkheimer FE. A multifractal approach to space-filling recovery for PET quantification. Medical Physics. 41: 112505. PMID 25370664 DOI: 10.1118/1.4898122  0.01
2014 Pazarentzos E, Mahul-Mellier AL, Datler C, Chaisaklert W, Hwang MS, Kroon J, Qize D, Osborne F, Al-Rubaish A, Al-Ali A, Mazarakis ND, Aboagye EO, Grimm S. IκΒα inhibits apoptosis at the outer mitochondrial membrane independently of NF-κB retention. The Embo Journal. 33: 2814-28. PMID 25361605 DOI: 10.15252/embj.201488183  1
2014 George GP, Pisaneschi F, Nguyen QD, Aboagye EO. Positron emission tomographic imaging of CXCR4 in cancer: challenges and promises. Molecular Imaging. 13. PMID 25341373 DOI: 10.2310/7290.2014.00041  1
2014 Kenny LM, Aboagye EO. Clinical translation of molecular imaging agents used in PET studies of cancer. Advances in Cancer Research. 124: 329-74. PMID 25287694 DOI: 10.1016/B978-0-12-411638-2.00010-0  1
2014 Trousil S, Lee P, Pinato DJ, Ellis JK, Dina R, Aboagye EO, Keun HC, Sharma R. Alterations of choline phospholipid metabolism in endometrial cancer are caused by choline kinase alpha overexpression and a hyperactivated deacylation pathway. Cancer Research. 74: 6867-77. PMID 25267063 DOI: 10.1158/0008-5472.CAN-13-2409  1
2014 Filipovi? A, Lombardo Y, Faronato M, Fronato M, Abrahams J, Aboagye E, Nguyen QD, d'Aqua BB, Ridley A, Green A, Rahka E, Ellis I, Recchi C, Przulj N, Sarajli? A, et al. Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells. Breast Cancer Research and Treatment. 148: 455-62. PMID 25248409 DOI: 10.1007/S10549-014-3119-Z  1
2014 Gallo J, Kamaly N, Lavdas I, Stevens E, Nguyen QD, Wylezinska-Arridge M, Aboagye EO, Long NJ. CXCR4-targeted and MMP-responsive iron oxide nanoparticles for enhanced magnetic resonance imaging. Angewandte Chemie (International Ed. in English). 53: 9550-4. PMID 25045009 DOI: 10.1002/anie.201405442  1
2014 Evans HL, Nguyen QD, Carroll LS, Kaliszczak M, Twyman FJ, Spivey AC, Aboagye EO. A bioorthogonal (68)Ga-labelling strategy for rapid in vivo imaging. Chemical Communications (Cambridge, England). 50: 9557-60. PMID 25012592 DOI: 10.1039/C4Cc03903C  1
2014 Witney TH, Pisaneschi F, Alam IS, Trousil S, Kaliszczak M, Twyman F, Brickute D, Nguyen QD, Schug Z, Gottlieb E, Aboagye EO. Preclinical evaluation of 3-18F-fluoro-2,2-dimethylpropionic acid as an imaging agent for tumor detection Journal of Nuclear Medicine. 55: 1506-1512. PMID 25012458 DOI: 10.2967/jnumed.114.140343  1
2014 Sala R, Nguyen QD, Patel CB, Mann D, Steinke JH, Vilar R, Aboagye EO. Phosphorylation status of thymidine kinase 1 following antiproliferative drug treatment mediates 3'-deoxy-3'-[18F]-fluorothymidine cellular retention. Plos One. 9: e101366. PMID 25003822 DOI: 10.1371/Journal.Pone.0101366  1
2014 Lavdas I, Miquel ME, McRobbie DW, Aboagye EO. Comparison between diffusion-weighted MRI (DW-MRI) at 1.5 and 3 tesla: a phantom study. Journal of Magnetic Resonance Imaging : Jmri. 40: 682-90. PMID 24925470 DOI: 10.1002/jmri.24397  1
2014 Schelhaas S, Wachsmuth L, Viel T, Honess DJ, Heinzmann K, Smith DM, Hermann S, Wagner S, Kuhlmann MT, Müller-Tidow C, Kopka K, Schober O, Schäfers M, Schneider R, Aboagye EO, et al. Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 3'-Deoxy-3'-¹⁸F-Fluorothymidine PET and Diffusion-Weighted MR Imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 983-8. PMID 24777288 DOI: 10.2967/jnumed.113.133348  1
2014 Mapelli P, Tam HH, Sharma R, Aboagye EO, Al-Nahhas A. Frequency and significance of physiological versus pathological uptake of 68Ga-DOTATATE in the pancreas: validation with morphological imaging. Nuclear Medicine Communications. 35: 613-9. PMID 24686250 DOI: 10.1097/MNM.0000000000000106  1
2014 Witney TH, Fortt R, Fortt RR, Aboagye EO. Preclinical assessment of carboplatin treatment efficacy in lung cancer by 18F-ICMT-11-positron emission tomography. Plos One. 9: e91694. PMID 24618809 DOI: 10.1371/journal.pone.0091694  1
2014 Witney TH, Carroll L, Alam IS, Chandrashekran A, Nguyen QD, Sala R, Harris R, DeBerardinis RJ, Agarwal R, Aboagye EO. A novel radiotracer to image glycogen metabolism in tumors by positron emission tomography. Cancer Research. 74: 1319-28. PMID 24590807 DOI: 10.1158/0008-5472.CAN-13-2768  1
2014 Gallo J, Alam IS, Jin J, Gu YJ, Aboagye EO, Wong WT, Long NJ. PET imaging with multimodal upconversion nanoparticles. Dalton Transactions (Cambridge, England : 2003). 43: 5535-45. PMID 24535647 DOI: 10.1039/c3dt53095g  1
2014 Trousil S, Hoppmann S, Nguyen QD, Kaliszczak M, Tomasi G, Iveson P, Hiscock D, Aboagye EO. Positron emission tomography imaging with 18f- labeled Zher2:2891 affibody for detection of HER2 expression and pharmacodynamic response to HER2-modulating therapies Clinical Cancer Research. 20: 1632-1643. PMID 24493830 DOI: 10.1158/1078-0432.CCR-13-2421  1
2014 Challapalli A, Sharma R, Hallett WA, Kozlowski K, Carroll L, Brickute D, Twyman F, Al-Nahhas A, Aboagye EO. Biodistribution and radiation dosimetry of deuterium-substituted 18F-fluoromethyl-[1, 2-2H4]choline in healthy volunteers. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 256-63. PMID 24492392 DOI: 10.2967/jnumed.113.129577  1
2014 George GP, Stevens E, Åberg O, Nguyen QD, Pisaneschi F, Spivey AC, Aboagye EO. Preclinical evaluation of a CXCR4-specific (68)Ga-labelled TN14003 derivative for cancer PET imaging. Bioorganic & Medicinal Chemistry. 22: 796-803. PMID 24365390 DOI: 10.1016/J.Bmc.2013.12.012  1
2014 Alam IS, Witney TH, Tomasi G, Carroll L, Twyman FJ, Nguyen QD, Aboagye EO. Radiolabeled RGD tracer kinetics annotates differential αvβ3 integrin expression linked to cell intrinsic and vessel expression Molecular Imaging and Biology. 16: 558-566. PMID 24310722 DOI: 10.1007/s11307-013-0710-3  1
2014 Pisaneschi F, Slade RL, Iddon L, George GP, Nguyen QD, Spivey AC, Aboagye EO. Synthesis of a new fluorine-18 glycosylated 'click' cyanoquinoline for the imaging of epidermal growth factor receptor. Journal of Labelled Compounds & Radiopharmaceuticals. 57: 92-6. PMID 24307532 DOI: 10.1002/Jlcr.3170  1
2014 Evans HL, Carroll L, Aboagye EO, Spivey AC. Bioorthogonal chemistry for (68) Ga radiolabelling of DOTA-containing compounds. Journal of Labelled Compounds & Radiopharmaceuticals. 57: 291-7. PMID 24307493 DOI: 10.1002/Jlcr.3153  1
2014 Challapalli A, Barwick T, Tomasi G, O' Doherty M, Contractor K, Stewart S, Al-Nahhas A, Behan K, Coombes C, Aboagye EO, Mangar S. Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer. Nuclear Medicine Communications. 35: 20-9. PMID 24201549 DOI: 10.1097/MNM.0000000000000014  1
2014 Schug Z, Peck B, Jones D, Zhang Q, Alam I, Witney T, Smethurst E, Grosskurth S, Harris A, Critchlow S, Aboagye E, Wakelam M, Schulze A, Gottlieb E. Acetyl-coA synthetase 2 promotes acetate utilization and maintains cell growth under metabolic stress Cancer and Metabolism. 2: 1-1. DOI: 10.1186/2049-3002-2-S1-O9  1
2014 Merchant S, Witney TH, Aboagye EO. Imaging as a pharmacodynamic and response biomarker in cancer Clinical and Translational Imaging. 2: 13-31. DOI: 10.1007/s40336-014-0049-z  1
2014 Aboagye EO, Aigbirhio FI, Allen P, Arent R, Arrowsmith RL, Banci G, Bagley MC, Bailey CD, Blake T, Bunt AJ, Bushby N, Carroll L, Cons BD, Cortezon F, Dilworth JR, et al. Abstracts of the 22nd International Isotope Society (UK Group) Symposium: Synthesis and applications of labelled compounds 2013 Journal of Labelled Compounds and Radiopharmaceuticals. DOI: 10.1002/jlcr.3523  1
2013 George GP, Pisaneschi F, Stevens E, Nguyen QD, Åberg O, Spivey AC, Aboagye EO. Scavenging strategy for specific activity improvement: application to a new CXCR4-specific cyclopentapeptide positron emission tomography tracer. Journal of Labelled Compounds & Radiopharmaceuticals. 56: 679-85. PMID 25196030 DOI: 10.1002/Jlcr.3095  1
2013 Trousil S, Carroll L, Kalusa A, Aberg O, Kaliszczak M, Aboagye EO. Design of symmetrical and nonsymmetrical N,N-dimethylaminopyridine derivatives as highly potent choline kinase alpha inhibitors. Medchemcomm. 2013: 693-696. PMID 24976941 DOI: 10.1039/C3MD00068K  1
2013 Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, et al. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research : Bcr. 15: R92. PMID 24286369 DOI: 10.1186/Bcr3493  1
2013 Kaliszczak M, Patel H, Kroll SH, Carroll L, Smith G, Delaney S, Heathcote DA, Bondke A, Fuchter MJ, Coombes RC, Barrett AG, Ali S, Aboagye EO. Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance. British Journal of Cancer. 109: 2356-67. PMID 24071597 DOI: 10.1038/Bjc.2013.584  1
2013 Challapalli A, Kenny LM, Hallett WA, Kozlowski K, Tomasi G, Gudi M, Al-Nahhas A, Coombes RC, Aboagye EO. 18F-ICMT-11, a caspase-3-specific PET tracer for apoptosis: Biodistribution and radiation dosimetry Journal of Nuclear Medicine. 54: 1551-1556. PMID 23949910 DOI: 10.2967/jnumed.112.118760  1
2013 Dart DA, Waxman J, Aboagye EO, Bevan CL. Visualising androgen receptor activity in male and female mice. Plos One. 8: e71694. PMID 23940781 DOI: 10.1371/journal.pone.0071694  0.01
2013 Carroll L, Evans HL, Aboagye EO, Spivey AC. Bioorthogonal chemistry for pre-targeted molecular imaging--progress and prospects. Organic & Biomolecular Chemistry. 11: 5772-81. PMID 23907155 DOI: 10.1039/C3Ob40897C  1
2013 Tietz O, Kamaly N, Smith G, Shamsaei E, Bhakoo KK, Long NJ, Aboagye EO. Design, synthesis and in vitro characterization of fluorescent and paramagnetic CXCR4-targeted imaging agents. American Journal of Nuclear Medicine and Molecular Imaging. 3: 372-83. PMID 23901361  1
2013 Zhao L, Ashek A, Wang L, Fang W, Dabral S, Dubois O, Cupitt J, Pullamsetti SS, Cotroneo E, Jones H, Tomasi G, Nguyen QD, Aboagye EO, El-Bahrawy MA, Barnes G, et al. Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments. Circulation. 128: 1214-24. PMID 23900048 DOI: 10.1161/CIRCULATIONAHA.113.004136  1
2013 Gallo J, Long NJ, Aboagye EO. Magnetic nanoparticles as contrast agents in the diagnosis and treatment of cancer. Chemical Society Reviews. 42: 7816-33. PMID 23788179 DOI: 10.1039/c3cs60149h  1
2013 Nguyen QD, Lavdas I, Gubbins J, Smith G, Fortt R, Carroll LS, Graham MA, Aboagye EO. Temporal and spatial evolution of therapy-induced tumor apoptosis detected by caspase-3-selective molecular imaging. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3914-24. PMID 23729364 DOI: 10.1158/1078-0432.CCR-12-3814  1
2013 Lavdas I, Behan KC, Papadaki A, McRobbie DW, Aboagye EO. A phantom for diffusion-weighted MRI (DW-MRI). Journal of Magnetic Resonance Imaging : Jmri. 38: 173-9. PMID 23576443 DOI: 10.1002/jmri.23950  1
2013 Kaliszczak M, Trousil S, Åberg O, Perumal M, Nguyen QD, Aboagye EO. A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth British Journal of Cancer. 108: 342-350. PMID 23322205 DOI: 10.1038/bjc.2012.576  1
2013 Willaime JMY, Turkheimer FE, Kenny LM, Aboagye EO. Quantification of intra-tumour cell proliferation heterogeneity using imaging descriptors of 18F fluorothymidine-positron emission tomography Physics in Medicine and Biology. 58: 187-203. PMID 23257054 DOI: 10.1088/0031-9155/58/2/187  1
2013 Coombes RC, Tat T, Miller ML, Reise JA, Mansi JL, Hadjiminas DJ, Shousha S, Elsheikh SE, Lam EW, Horimoto Y, El-Bahrawy M, Aboagye EO, Contractor KB, Shaw JA, Walker RA, et al. An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study). Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 924-30. PMID 23233650 DOI: 10.1093/annonc/mds594  1
2013 Sala R, Nguyen Q, Patel C, Mann D, Steinke JHG, Vilar R, Aboagye EO. Abstract 2660: Regulation of 18F-fluorothymidine uptake by thymidine kinase 1 protein phosphorylation. Cancer Research. 73: 2660-2660. DOI: 10.1158/1538-7445.Am2013-2660  1
2012 Carroll L, Perumal M, Vasdev N, Robins E, Aboagye EO. Radiosynthesis and in vivo tumor uptake of 2-deoxy-2-[(18)F]fluoro-myo-inositol. Bioorganic & Medicinal Chemistry Letters. 22: 6148-50. PMID 22944120 DOI: 10.1016/J.Bmcl.2012.08.022  1
2012 Fortt R, Smith G, Awais RO, Luthra SK, Aboagye EO. Automated GMP synthesis of [(18)F]ICMT-11 for in vivo imaging of caspase-3 activity. Nuclear Medicine and Biology. 39: 1000-5. PMID 22575271 DOI: 10.1016/j.nucmedbio.2012.03.004  1
2012 Contractor K, Challapalli A, Tomasi G, Rosso L, Wasan H, Stebbing J, Kenny L, Mangar S, Riddle P, Palmieri C, Al-Nahhas A, Sharma R, Turkheimer F, Coombes RC, Aboagye E. Imaging of cellular proliferation in liver metastasis by [18F]fluorothymidine positron emission tomography: effect of therapy. Physics in Medicine and Biology. 57: 3419-33. PMID 22572708 DOI: 10.1088/0031-9155/57/11/3419  1
2012 Aboagye EO, Gilbert FJ, Fleming IN, Beer AJ, Cunningham VJ, Marsden PK, Visvikis D, Gee AD, Groves AM, Kenny LM, Cook GJ, Kinahan PE, Myers M, Clarke L. Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials. European Radiology. 22: 1465-78. PMID 22476502 DOI: 10.1007/S00330-011-2311-3  1
2012 Contractor K, Aboagye EO, Jacob J, Challapalli A, Coombes RC, Stebbing J. Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and [ 18F] 3́-deoxy-3́- fluorothymidine PET: A pilot study Biomarkers in Medicine. 6: 231-233. PMID 22448798 DOI: 10.2217/bmm.12.11  1
2012 Contractor KB, Kenny LM, Coombes CR, Turkheimer FE, Aboagye EO, Rosso L. Evaluation of limited blood sampling population input approaches for kinetic quantification of [18F]fluorothymidine PET data. Ejnmmi Research. 2: 11. PMID 22444834 DOI: 10.1186/2191-219X-2-11  1
2012 Smith G, Sala R, Carroll L, Behan K, Glaser M, Robins E, Nguyen QD, Aboagye EO. Synthesis and evaluation of nucleoside radiotracers for imaging proliferation. Nuclear Medicine and Biology. 39: 652-65. PMID 22321533 DOI: 10.1016/j.nucmedbio.2011.12.002  1
2012 Witney TH, Alam IS, Turton DR, Smith G, Carroll L, Brickute D, Twyman FJ, Nguyen QD, Tomasi G, Awais RO, Aboagye EO. Evaluation of deuterated 18F- and 11C-labeled choline analogs for cancer detection by positron emission tomography Clinical Cancer Research. 18: 1063-1072. PMID 22235095 DOI: 10.1158/1078-0432.CCR-11-2462  1
2012 Evans HL, Slade RL, Carroll L, Smith G, Nguyen QD, Iddon L, Kamaly N, Stöckmann H, Leeper FJ, Aboagye EO, Spivey AC. Copper-free click--a promising tool for pre-targeted PET imaging. Chemical Communications (Cambridge, England). 48: 991-3. PMID 22158912 DOI: 10.1039/C1Cc16220A  1
2012 Vengadabady L, Thielemans K, McCabe D, Challapalli A, Spinks TJ, Aboagye E. Comparing respiratory and patient movement during dynamic PET Ieee Nuclear Science Symposium Conference Record. 4005-4008. DOI: 10.1109/NSSMIC.2012.6551917  1
2011 Contractor K, Challapalli A, Barwick T, Winkler M, Hellawell G, Hazell S, Tomasi G, Al-Nahhas A, Mapelli P, Kenny LM, Tadrous P, Coombes RC, Aboagye EO, Mangar S. Use of [ 11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression Clinical Cancer Research. 17: 7673-7683. PMID 22038995 DOI: 10.1158/1078-0432.CCR-11-2048  1
2011 Glaser M, Goggi J, Smith G, Morrison M, Luthra SK, Robins E, Aboagye EO. Improved radiosynthesis of the apoptosis marker 18F-ICMT11 including biological evaluation Bioorganic and Medicinal Chemistry Letters. 21: 6945-6949. PMID 22030029 DOI: 10.1016/j.bmcl.2011.10.001  1
2011 Contractor KB, Kenny LM, Stebbing J, Rosso L, Ahmad R, Jacob J, Challapalli A, Turkheimer F, Al-Nahhas A, Sharma R, Coombes RC, Aboagye EO. [18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7664-72. PMID 22028493 DOI: 10.1158/1078-0432.CCR-11-0783  1
2011 Contractor KB, Kenny LM, Stebbing J, Challapalli A, Al-Nahhas A, Palmieri C, Shousha S, Lewis JS, Hogben K, De Nguyen Q, Coombes RC, Aboagye EO. Biological basis of [11C]choline-positron emission tomography in patients with breast cancer: Comparison with [18F]fluorothymidine positron emission tomography Nuclear Medicine Communications. 32: 997-1004. PMID 21862943 DOI: 10.1097/MNM.0b013e328349567b  1
2011 Leyton J, Iddon L, Perumal M, Indrevoll B, Glaser M, Robins E, George AJT, Cuthbertson A, Luthra SK, Aboagye EO. Targeting somatostatin receptors: Preclinical evaluation of novel 18F-fluoroethyltriazole-Tyr3-octreotate analogs for PET Journal of Nuclear Medicine. 52: 1441-1448. PMID 21852355 DOI: 10.2967/jnumed.111.088906  1
2011 Nguyen QD, Perumal M, Waldman TA, Aboagye EO. Glucose metabolism measured by [¹⁸F]fluorodeoxyglucose positron emission tomography is independent of PTEN/AKT status in human colon carcinoma cells. Translational Oncology. 4: 241-8. PMID 21804920 DOI: 10.1593/Tlo.11118  1
2011 Golinska M, Troy H, Chung YL, McSheehy PM, Mayr M, Yin X, Ly L, Williams KJ, Airley RE, Harris AL, Latigo J, Perumal M, Aboagye EO, Perrett D, Stubbs M, et al. Adaptation to HIF-1 deficiency by upregulation of the AMP/ATP ratio and phosphofructokinase activation in hepatomas. Bmc Cancer. 11: 198. PMID 21612605 DOI: 10.1186/1471-2407-11-198  1
2011 Iddon L, Leyton J, Indrevoll B, Glaser M, Robins EG, George AJT, Cuthbertson A, Luthra SK, Aboagye EO. Synthesis and in vitro evaluation of [18F]fluoroethyl triazole labelled [Tyr3]octreotate analogues using click chemistry Bioorganic and Medicinal Chemistry Letters. 21: 3122-3127. PMID 21458258 DOI: 10.1016/j.bmcl.2011.03.016  1
2011 Smith G, Zhao Y, Leyton J, Shan B, Nguyen QD, Perumal M, Turton D, Årstad E, Luthra SK, Robins EG, Aboagye EO. Radiosynthesis and pre-clinical evaluation of [(18)F]fluoro-[1,2-(2)H(4)]choline. Nuclear Medicine and Biology. 38: 39-51. PMID 21220128 DOI: 10.1016/j.nucmedbio.2010.06.012  1
2011 Pisaneschi F, Sejberg JJP, Blain C, Ng WH, Aboagye EO, Spivey AC. 2-Substituted-2,3-dihydro-1 H -quinolin-4-ones via acid-catalyzed tandem rupe rearrangement-donnelly-farrell ring closure of 2-(3′-hydroxypropynyl) anilines Synlett. 241-244. DOI: 10.1055/S-0030-1259309  1
2010 Heathcote DA, Patel H, Kroll SH, Hazel P, Periyasamy M, Alikian M, Kanneganti SK, Jogalekar AS, Scheiper B, Barbazanges M, Blum A, Brackow J, Siwicka A, Pace RD, Fuchter MJ, ... ... Aboagye EO, et al. A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration. Journal of Medicinal Chemistry. 53: 8508-22. PMID 21080703 DOI: 10.1021/Jm100732T  1
2010 Pisaneschi F, Nguyen QD, Shamsaei E, Glaser M, Robins E, Kaliszczak M, Smith G, Spivey AC, Aboagye EO. Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core: synthesis and biological evaluation. Bioorganic & Medicinal Chemistry. 18: 6634-45. PMID 20797871 DOI: 10.1016/J.Bmc.2010.08.004  1
2010 Hatt M, Cheze-Le Rest C, Aboagye EO, Kenny LM, Rosso L, Turkheimer FE, Albarghach NM, Metges JP, Pradier O, Visvikis D. Reproducibility of 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET tumor volume measurements. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 1368-76. PMID 20720054 DOI: 10.2967/Jnumed.110.078501  1
2010 Gray KR, Contractor KB, Kenny LM, Al-Nahhas A, Shousha S, Stebbing J, Wasan HS, Coombes RC, Aboagye EO, Turkheimer FE, Rosso L. Kinetic filtering of [(18)F]Fluorothymidine in positron emission tomography studies. Physics in Medicine and Biology. 55: 695-709. PMID 20071760 DOI: 10.1088/0031-9155/55/3/010  1
2009 Pardo OE, Latigo J, Jeffery RE, Nye E, Poulsom R, Spencer-Dene B, Lemoine NR, Stamp GW, Aboagye EO, Seckl MJ. The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Research. 69: 8645-51. PMID 19903855 DOI: 10.1158/0008-5472.CAN-09-1576  1
2009 Leyton J, Smith G, Zhao Y, Perumal M, Nguyen QD, Robins E, Arstad E, Aboagye EO. [18F]fluoromethyl-[1,2-2H4]-choline: a novel radiotracer for imaging choline metabolism in tumors by positron emission tomography. Cancer Research. 69: 7721-8. PMID 19773436 DOI: 10.1158/0008-5472.CAN-09-1419  1
2009 Tennant DA, Frezza C, MacKenzie ED, Nguyen QD, Zheng L, Selak MA, Roberts DL, Dive C, Watson DG, Aboagye EO, Gottlieb E. Reactivating HIF prolyl hydroxylases under hypoxia results in metabolic catastrophe and cell death. Oncogene. 28: 4009-21. PMID 19718054 DOI: 10.1038/onc.2009.250  1
2009 Ali S, Heathcote DA, Kroll SH, Jogalekar AS, Scheiper B, Patel H, Brackow J, Siwicka A, Fuchter MJ, Periyasamy M, Tolhurst RS, Kanneganti SK, Snyder JP, Liotta DC, Aboagye EO, et al. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Research. 69: 6208-15. PMID 19638587 DOI: 10.1158/0008-5472.Can-09-0301  1
2009 Chapon C, Jackson JS, Aboagye EO, Herlihy AH, Jones WA, Bhakoo KK. An in vivo multimodal imaging study using MRI and PET of stem cell transplantation after myocardial infarction in rats. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 11: 31-8. PMID 18773246 DOI: 10.1007/S11307-008-0174-Z  1
2008 Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M, Spinks TJ, McParland B, Cohen PS, Hui AM, Palmieri C, Osman S, Glaser M, Turton D, Al-Nahhas A, Aboagye EO. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients Journal of Nuclear Medicine. 49: 879-886. PMID 18483090 DOI: 10.2967/jnumed.107.049452  1
2007 Chan F, Sun C, Perumal M, Nguyen QD, Bavetsias V, McDonald E, Martins V, Wilsher NE, Raynaud FI, Valenti M, Eccles S, Te Poele R, Workman P, Aboagye EO, Linardopoulos S. Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Molecular Cancer Therapeutics. 6: 3147-57. PMID 18089709 DOI: 10.1158/1535-7163.MCT-07-2156  1
2006 Leyton J, Lockley M, Aerts JL, Baird SK, Aboagye EO, Lemoine NR, McNeish IA. Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography imaging. Cancer Research. 66: 9178-85. PMID 16982761 DOI: 10.1158/0008-5472.CAN-06-1539  1
2005 Buluwela L, Pike J, Mazhar D, Kamalati T, Hart SM, Al-Jehani R, Yahaya H, Patel N, Sarwarl N, Heathcote DA, Schwickerath O, Phoenix F, Hill R, Aboagye E, Shousha S, et al. Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-α and the transcriptional repressor PLZF Gene Therapy. 12: 452-460. PMID 15647773 DOI: 10.1038/  1
2004 Groot-Wassink T, Aboagye EO, Wang Y, Lemoine NR, Keith WN, Vassaux G. Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice Cancer Research. 64: 4906-4911. PMID 15256462 DOI: 10.1158/0008-5472.CAN-04-0426  1
2004 Groot-Wassink T, Aboagye EO, Wang Y, Lemoine NR, Reader AJ, Vassaux G. Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal Molecular Therapy. 9: 436-442. PMID 15006611 DOI: 10.1016/j.ymthe.2003.12.001  1
2002 Groot-Wassink T, Aboagye EO, Glaser M, Lemoine NR, Vassaux G. Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene Human Gene Therapy. 13: 1723-1735. PMID 12396625 DOI: 10.1089/104303402760293565  1
2001 Bhujwalla ZM, Artemov D, Aboagye E, Ackerstaff E, Gillies RJ, Natarajan K, Solaiyappan M. The physiological environment in cancer vascularization, invasion and metastasis Novartis Foundation Symposium. 240: 23-38. PMID 11727932 DOI: 10.1002/0470868716.Ch3  1
2001 Aboagye EO, Price PM, Jones T. In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography Drug Discovery Today. 6: 293-302. DOI: 10.1016/S1359-6446(01)01684-1  1
2000 Saleem A, Yap J, Osman S, Brady F, Suttle B, Lucas SV, Jones T, Price PM, Aboagye EO. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. Lancet. 355: 2125-31. PMID 10902627 DOI: 10.1016/S0140-6736(00)02380-1  1
1999 Bhujwalla ZM, Aboagye EO, Gillies RJ, Chacko VP, Mendola CE, Backer JM. Nm23-transfected MDA-MB-435 human breast carcinoma cells form tumors with altered phospholipid metabolism and pH: A 31P nuclear magnetic resonance study in vivo and vitro Magnetic Resonance in Medicine. 41: 897-903. PMID 10332871 DOI: 10.1002/(SICI)1522-2594(199905)41:5<897::AID-MRM7>3.0.CO;2-T  1
1998 Aboagye EO, Bhujwalla ZM, He Q, Glickson JD. Evaluation of lactate as a 1H nuclear magnetic resonance spectroscopy index for noninvasive prediction and early detection of tumor response to radiation therapy in EMT6 tumors. Radiation Research. 150: 38-42. PMID 9650600 DOI: 10.2307/3579643  1
1998 Aboagye EO, Maxwell RJ, Horsman MR, Lewis AD, Workman P, Tracy M, Griffiths JR. The relationship between tumour oxygenation determined by oxygen electrode measurements and magnetic resonance spectroscopy of the fluorinated 2-nitroimidazole SR-4554. British Journal of Cancer. 77: 65-70. PMID 9459147 DOI: 10.1038/bjc.1998.10  1
1995 Aboagye EO, Graham MA, Lewis AD, Workman P, Kelson AB, Tracy M. Development and validation of a solid-phase extraction and high-performance liquid chromatographic assay for a novel fluorinated 2-nitroimidazole hypoxia probe (SR-4554) in Balb/c mouse plasma. Journal of Chromatography. B, Biomedical Applications. 672: 125-32. PMID 8590924 DOI: 10.1016/0378-4347(95)00204-V  1
Show low-probability matches.